Angiotensin receptor blockers and breast cancer risk: a meta-analysis.
Some studies reported that angiotensin receptor blockers (ARBs) reduced the risk of breast cancer. However, other studies did not show similar results. The PubMed and EMBASE databases were searched. The strength of the association between ARBs and the risk of breast cancer was measured by odds ratio (OR) and 95% confidence interval (CI). Eight eligible studies with 1,994,880 individuals were considered for this meta-analysis. ARBs was not associated with the risk of breast cancer (OR=0.93; 95% CI: 0.81-1.06; I2=86%). In the subgroup analysis of race, a significantly decreased breast cancer risk were observed in Asians (OR=0.62; 95% CI: 0.53-0.73; I2=0%). However, a significantly increased breast cancer risk were observed in Caucasians (OR=1.08; 95% CI: 1.02-1.13; I2=28%). This study provided evidence that ARBs was associated with decreased breast cancer in Asians and increased risk of breast cancer in Caucasians.